Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to 3-month paliperidone palmitate in schizophrenia
2015-004835-10Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Achieving Symptomatic Remission Based on Positive and Negative Syndrome Scale (PANSS). Started Jan 2016; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2015-004835-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004835-10.